January 10, 2014 Top Pros’ Top Picks Stocks of biotechnology companies that reach major inflection points tend to outperform for several years. And our top speculative idea is a company that made a major leap forward in 2013, suggests Jay Silverman, editor of The Medical Technology Stock Letter. Novavax (NVAX) is executing its clinical plan[…]
Category: Publicity
Moneyshow – Top Pros’ Top Picks (11-19-13)
November 19, 2013 Novavax: Progress Against the Flu One of our core biotech holdings surprised us by publishing positive results in the most recent online edition of The New England Journal of Medicine (NEJM), notes John McCamant, editor of The Medical Technology Stock Letter. Novavax (NVAX) released its Phase I trial of 284 subjects injected[…]
Forbes (9-23-13)
Biotechs Are Back In Favor Amid Plethora Of Positive Developments Written By Gene Marcial, Contributor It isn’t often that the biotechnology industry gets swamped with plenty of good news, but that’s what has been happening in recent months. Not surprisingly, they have attracted investor interest. A number of new drug approvals, affirmative data, and accelerated[…]
Moneyshow – The Daily Guru (8-26-13)
August 26, 2013 Biotechs Target Pain and Flu by Steven Halpern for The Daily Guru The Daily Guru Biotechs Target Pain and Flu. Jay Silverman, biotech analyst at The Medical Technology Stock Letter, looks at some favorite biotech stocks that are addressing potentially large, new markets. Steve Halpern: We’re here today with Jay Silverman of[…]
WSJ – Why Following the Winners Is for Losers (1-3-14)
January 3, 2014 Why Following the Winners Is for Losers by Mark Hulbert “Past performance is no guarantee of future results.” This phrase, ubiquitous in the small print of financial products, often falls on deaf ears, according to Adam Reed, a finance professor at the University of North Carolina at Chapel Hill. “Investors have a[…]
Moneyshow – The Daily Guru (11-11-13)
November 11, 2013 Sector Pullback Makes Biotech a Buy by Steven Halpern for The Daily Guru Despite the fact that the biotech sector has faced some setbacks recently, Jay Silverman, editor of Medical Technology Stock Letter, is confident it’s only the case of a normal correction. Steve Halpern: We’re here today with biotech sector expert,[…]
UT San Diego – Biotech (9-23-13)
September 23, 2013 Isis rises again on drug data by Bradley J. Fikes for The Union Tribune San Diego CARLSBAD — Shares of Isis Pharmaceuticals jumped up to 10 percent Monday after it reported more good clinical trial data for . Isis reached an intraday high of $39.83 before closing Monday at $38.48, up 6.7 percent[…]
Moneyshow – The Daily Guru (7-11-13)
July 11, 2013 Best Bets in Biotech Written By Steven Halpern for The Daily Guru The Daily Guru Best Bets in Biotech. With the US facing an ageing population and Obamacare going online next year, biotech is about to enter its golden age, says John McCamant of Medical Technology Stock Letter. Steven Halpern: We’re here[…]
Moneyshow – Profits in Pain Prevention (12-20-13)
December 23, 2013 Profits in Pain Prevention The Medical Technology Stock Letter had one of the best performing stocks in this past year’s Top Picks special; here, Jay Silverman updates his view on this biotech winner and highlights some potential new leaders for the coming year. Steve Halpern: We’re here today with biotech expert Jay Silverman[…]
The Life Sciences Report (9-26-13)
September 26, 2013 The Life Sciences Report: John McCamant Scans Under the Radar for Promising Biotechs by : Peter Byrne The Life Sciences Report: The medical biotech sector has generally been going great guns in 2013. Is there a seasonal aspect to the overall performance of biotech stocks? Are some seasons preferable to other seasons[…]
UT San Diego – Biotech (9-19-13)
September 19, 2013 Isis jumps on drug trial data by Bradley J. Fikes for The Union Tribune San Diego Isis Pharmaceuticals shares jumped 14 percent Thursday after the biotech company released positive preliminary Phase 1 results for its spinal muscular atrophy drug. Shares of Carlsbad-based Isis closed at $36.27, up $4.47 from Wednesday. The company’s market[…]
Forbes (5-27-13)
May 27, 2013 Tiny Biotech Developing Drugs Akin To Biogen’s Rituxan Seen As Potential Buyout Bet Written By Gene Marcial, Contributor Welcome to the super-sized Tiny Biotech Developing Drugs Akin To Biogen’s Rituxan Seen As Potential Buyout Bet. Unfortunately for investors in the arcane world of biotechnology, biotech stocks haven’t fully participated in the market’s[…]